Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Tapentadol price, strengths & recalls

Pharmacies pay $432.80 for 30 tablets of Tapentadol 100 mg tablet this week, and from $255.25 to $1,050.41 across its 6 priced strengths and forms. 4 manufacturers make it. Its official label last changed on March 4, 2026.

Generic
Pharmacies pay$432.80for 30 tablets of 100 mg tablet-0.4% in 4 weeks
Fair cash price
$508.22
Strengths
6
Makers
4
Updated
Nov 11

Tapentadol price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
50 mg (12 hr) extended-release tablet$12.15$364.55 / 30 tablets-1.7%
100 mg (12 hr) extended-release tablet$21.34$640.09 / 30 tablets-0.7%
200 mg (12 hr) extended-release tablet$35.01$1,050.41 / 30 tablets-0.9%
20 mg/mL oral solutionNot priced this week
50 mg tablet$8.51$255.25 / 30 tablets-3.9%
75 mg tablet$10.16$304.72 / 30 tablets-4.6%
100 mg tablet$14.43$432.80 / 30 tablets-0.4%

The lowest cost per tablet is 50 mg tablet at $8.51. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recallsNone on record

What did you pay for tapentadol? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedMarch 4, 2026
Version3
EffectiveFeb 26, 2026
Read the label

These highlights do not include all the information needed to use Tapentadol extended-release tablets safely and effectively. See full prescribing information for tapentadol extended-release tablet Tapentadol extended-release tablet for oral use C-II Initial U.S. Approval: 2008

This drug has a boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF TAPENTADOL EXTENDED-RELEASE TABLETS

Addiction, Abuse, and Misuse

Because the use of tapentadol extended-release tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death assess, each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1)].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of tapentadol extended-release tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of tapentadol extended-release tablets are essential. Instruct patients to swallow tapentadol extended-release tablets whole; crushing, chewing, or dissolving tapentadol extended-release tablets can cause rapid release and absorption of a potentially fatal dose of tapentadol [see Warnings and Precautions (5.2)].

Accidental Ingestion

Accidental ingestion of even one dose of tapentadol extended-release tablets, especially by children, can result in a fatal overdose of tapentadol [see Warnings and Precautions (5.2)].

Interaction with Alcohol

Instruct patients not to consume alcoholic beverages or use prescription or nonprescription products that contain alcohol while taking tapentadol extended-release tablets. The co-ingestion of alcohol with tapentadol extended-release tablets may result in increased plasma tapentadol levels and a potentially fatal overdose of tapentadol [see Warnings and Precautions (5.2, 5.3)].

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of tapentadol extended-release tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3), Drug Interactions (7)].

Neonatal Opioid Withdrawal Syndrome (NOWS)

If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.4)].

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.5)].

WARNING: SERIOUS LIFE-THREATENING RISKS FROM USE OF TAPENTADOL extended-release tablet

See full prescribing information for complete boxed warning.

Tapentadol extended-release tablets expose users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk before prescribing and reassess regularly for development of these behaviors or conditions. (5.1)

Serious, life-threatening, or fatal respiratory depression may occur, especially upon initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of tapentadol extended-release tablets are essential. Instruct patients to swallow tapentadol extended-release tablets whole to avoid exposure to a potentially fatal dose of tapentadol. (2.1, 5.2)

Accidental ingestion of tapentadol extended-release tablets, especially in children, can result in fatal overdose of tapentadol. (5.2)

Instruct patients not to consume alcohol or any products containing alcohol while taking tapentadol extended-release tablets because co-ingestion can result in fatal plasma tapentadol levels. (5.3)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.3, 7)

If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. (5.4)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (5.5)

Recent major changes (as listed on the label)

Boxed Warning | 12/2023 |

Indications and Usage (1) | 12/2023 |

Dosage and Administration (2.1, 2.3, 2.4) | 12/2023 |

Warnings and Precautions (5.6) | 12/2023 |

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA200533 · Collegium Pharm Inc
First approved
August 25, 2011 (15 years ago)
Latest approved change
June 18, 2026
Approved label
PDF, Dec 23, 2025
Generic makers
3 approved generic applications on the market
Last patent listed
March 22, 2029

Tapentadol questions

How much does tapentadol cost without insurance?

Pharmacies pay about $432.80 for 30 tablets of tapentadol 100 mg tablet ($14.43 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $508.22. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is tapentadol in shortage?

No shortage is reported for tapentadol right now. We check the national shortage list every day.

Has tapentadol been recalled?

No recalls are on record for tapentadol.

When did the tapentadol label last change?

The official label was last updated on March 4, 2026 (version 3). See what changed.

Talk about tapentadol

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.